Lamivudine treatment for chronic hepatitis B infection in children unresponsive to interferon

Corina Hartman, Drora Berkowitz, Daniel Shouval, Orly Eshach-Adiv, Bian Hino, Nurit Rimon, Iehudith Satinger, Tzipi Kra-Oz, Nily Daudi, Raanan Shamir*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Background/aims. Lamivudine is a potent inhibitor of hepatitis B virus (HBV) replication. This prospective open study reports the results of lamivudine treatment in children with chronic hepatitis B infection who did not respond to previous interferon treatment. Patients and methods. Lamivudine, 3 mg/kg/day (maximum, 100 mg/day), was given for 52 weeks to 20 children and adolescents, ages 8.5 to 19 years, with chronic hepatitis B infection who had been treated with interferon 2 to 5 years earlier. We evaluated virologic and biochemical responses, the occurrence of YMDD mutants and adverse effects. Results. All children were HBV DNA+, hepatitis B e antigen (HBeAg)+/anti-hepatitis B e antibody- at start of treatment. At the end of 1 year, HBV DNA declined by 95% in all patients, and 8 of 18 (44%) had sustained undetectable HBV DNA by hybridization assay. Median pretreatment alanine aminotransferase (ALT) × 1.5 upper limit of normal decreased to ALT × 0.9 upper limit of normal after 1 year. One child became HBeAg-negative. YMDD mutants were detected in 11 of 17 (65%) children after 1 year of lamivudine treatment. Among children with YMDD mutant variants, 54% maintained normal ALT values and 45% had undetectable HBV DNA by hybridization assay. No adverse effects were observed. Conclusions. Children with chronic hepatitis B infection treated with lamivudine after failure of interferon therapy had decreased HBV replication and improved ALT values. However, lamivudine treatment resulted in an exceptionally high rate of lamivudine-resistant mutants and low HBeAg seroconversion rate.

Original languageEnglish
Pages (from-to)224-228
Number of pages5
JournalPediatric Infectious Disease Journal
Volume22
Issue number3
DOIs
StatePublished - 1 Mar 2003
Externally publishedYes

Keywords

  • Children
  • Chronic hepatitis B
  • Lamivudine
  • Lamivudine-resistant mutants

Fingerprint

Dive into the research topics of 'Lamivudine treatment for chronic hepatitis B infection in children unresponsive to interferon'. Together they form a unique fingerprint.

Cite this